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Intermittent claudication is a common and debil-
itating condition. Approximately 0.5% to 2% of men
aged 45 to 69 years will have symptoms of intermit-
tent claudication.1,2 The majority are treated conser-
vatively. In 1959, Gillespie wrote that “as vasodila-
tors do not increase calf muscle blood flow, and
often decrease it, prescribing them for intermittent
claudication is useless.”3 Since that time, a number
of drugs have been tried in patients with intermit-
tent claudication with limited success. 
The discovery that nitric oxide is a potent
vasodilator of both arteries and veins lead us to
reassess the role of nitrates in intermittent claudica-
tion. Previous studies investigating the use of
nitrates in claudication looked at the long-term
administration of nitrates and the subsequent
effect.4 A problem with such studies is that it may be
difficult to distinguish a direct pharmacological
effect from the effect of development of a collateral
circulation. Even with no treatment, 75% of patients
with intermittent claudication will have an improve-
ment in or stabilization of their symptoms.5 Our aim
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Purpose: The goal of the present study was to assess the immediate effect of sublingual
glyceryl trinitrate (GTN) in patients with intermittent claudication.
Methods: We conducted a randomized, double-blind, placebo-controlled crossover study.
Inclusion criteria consisted of history of intermittent claudication, resting ankle brachial
pressure index (ABPI) of 1.00 or less, a 20% or greater fall in ABPI after exercise, and
maximum walking distance (MWD) of less than 250 m. Patients already receiving
nitrates were excluded. In study 1, patients (n = 25) underwent a standard exercise test
after randomization to receive either 800 µg of sublingual GTN or placebo. The post-
exercise ABPI was recorded. Then, the crossover portion of the study was performed. In
study 2, patients (n = 22) had their claudication distance and MWD measured. They
then were randomized to receive either GTN or placebo spray, and the exercise test was
repeated, with the claudication distance and MWD recorded, followed by the crossover
portion of the study. Statistical analysis was performed with the Wilcoxon matched pairs
signed ranks test and the Mann-Whitney U test.
Results: In study 1, the median postexercise ABPIs for placebo and GTN were 0.29 and
0.36 (P = .0001). In study 2, the median claudication distance for both placebo and
GTN groups was 70 m (P = .59). The median MWD for the placebo and GTN groups
was 105 and 125 m (P = .0084)
Conclusion: GTN can decrease the fall in ABPI after exercise and increase the MWD. 
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was to assess the immediate effect of a single dose of
sublingual GTN in patients with intermittent claudi-
cation; this would measure an immediate pharmaco-
logical effect rather than an effect due to the devel-
opment of a collateral circulation. 
PATIENTS AND METHODS
Study 1. This study was performed to deter-
mine whether GTN made an objective difference to
the ankle brachial pressure index (ABPI) after a stan-
dardized exercise test compared with placebo.
Patients (n = 25) of a median age of 70 years (age
range, 59 to 75 years; 18 men and 7 women; 7
smokers; 5 diabetics) who were attending the vascu-
lar laboratory for treadmill assessment of their inter-
mittent claudication were recruited (Table I).
Inclusion criteria were (1) a history of intermittent
claudication, (2) a resting ABPI of 1.00 or less, and
(3) a 20% or greater fall in ABPI after a standard
exercise test. Patients already receiving nitrates were
excluded. The resting ABPI was assessed with a
sphygmomanometer, and a hand-held Doppler was
used to record the brachial artery pressure and the
maximum ankle pressure in either the dorsalis pedis,
posterior tibial, or peroneal artery. The protocol is
summarized in Fig 1. The standard exercise test was
performed using a treadmill set at 3.2 km/h on a
10% gradient for 2 minutes. If the patients could not
manage this protocol, the maximum speed and time
they could manage was recorded, and this same reg-
imen was used for all subsequent tests for each indi-
vidual. Postexercise ABPI was recorded, and the
patient was immediately returned to the treadmill.
Patients then were randomized by computer-gener-
ated random numbers to receive either 800 µg of
sublingual GTN by a metered-dose spray (t1/2 = 2.5
minutes) or two puffs of a placebo spray. The exer-
cise was repeated at the same speed and for the same
length of time as in exercise 1. The postexercise
ABPI was recorded, and this was followed immedi-
ately by the cross-over portion of the study, with
patients receiving either GTN or placebo spray
before repeating exercise 1, followed by repeat mea-
surement of the ABPI. At completion, patients were
asked whether they had developed a headache.
Double blinding was achieved by the drug or place-
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Fig 1. Flow diagram to summarize study 1.
Table I. Patient demographics for studies 1 and 2
Study 1 Study 2
Number of patients 25 22
Median age (interquartile range) 70 69
(59 to 75) (60 to 73)
Male 18 16
Smoker 7 5
Diabetic 5 3
bo being administered by an independent observer
such that patient and technician were unaware of the
formulation used.
Study 2. This study was performed to deter-
mine whether GTN had any effect on the claudica-
tion distance (CD) and maximum walking distance
(MWD) compared with placebo. Patients (n = 22)
of a median age of 69 years (age range, 60 to 73
years; 16 men and 6 women; 5 smokers; 3 diabetics)
who were attending the vascular laboratory for
treadmill assessment of their intermittent claudica-
tion were recruited (Table I). Inclusion criteria were
the same as those in study 1. Patients already receiv-
ing nitrates were excluded. The protocol is summa-
rized in Fig 2. The ABPI was measured, and then
the patients walked on a treadmill set at 3.2 km/h
on a 10% gradient. The distance to the onset of clau-
dication pain was recorded (CD). They then were
asked to walk for as long as they could tolerate the
pain so the MWD could be recorded. Patients were
blinded to the reading on the tachometer on the
treadmill. The postexercise ABPI then was recorded.
Eligible patients were given a rest of 10 minutes
from the time of completing the exercise to
remounting the treadmill. At this time, they were
randomized to receive either 800 µg of GTN or a
placebo spray, as in study 1. The exercise was repeat-
ed, and patients were asked to indicate the onset of
claudication pain. They then were asked to walk for
as long as they could tolerate the pain. After an addi-
tional 10-minute rest, the cross-over portion of the
study was completed, with either GTN or placebo
spray being administered before the final exercise
test. At completion, patients were asked whether
they had developed a headache.
Both studies were of randomized, double-blind,
placebo-controlled design. Written informed con-
sent was obtained from patients, and the study was
approved by the local ethics committee. A Medicines
(exemption from licenses, special cases, and miscel-
laneous provisions) order 1972 had been obtained.
The diagrams produced for the results visually
suggest that the data were not normally distributed.
Using a statistical software package, three different
tests on our data confirmed them to be not normal-
ly distributed (Kurtosis, Skewness, and Kolmogarov-
Smirnov goodness-of-fit test for normal distribu-
tion); therefore, nonparametric tests were used.
Results in the text are expressed as median values
(interquartile range) unless stated otherwise, and
statistical analysis was performed with Wilcoxon’s
matched pairs signed rank test for related pairs and
the Mann-Whitney U test for unrelated pairs. 
RESULTS
Study 1. To exclude possible temporal and car-
ryover effects, results were first analyzed according
to whether GTN or placebo was administered first.
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Fig 2. Flow diagram to summarize study 2.
These results are summarized in Table II; they con-
firm that there was no such effect. Fig 3 shows the
pooled results. The median resting brachial pressure
was 170 mm Hg (range, 150 to 190 mm Hg), and
the median maximum ankle pressure was 100 mm
Hg (range, 80 to 125 mm Hg), giving a median
resting ABPI of 0.67 (range, 0.47 to 0.79). After
exercise and placebo spray, the median brachial pres-
sure was 190 (159 to 210), and the median maxi-
mum ankle pressure was 50 mm Hg (40 to 80 mm
Hg), giving a median ABPI of 0.29 (0.2 to 0.50).
After exercise and GTN, the median brachial pres-
sure was 180 mm Hg (150 to 198 mm Hg), and the
median maximum ankle pressure was 60 mm Hg
(40 to 90 mm Hg), giving a median ABPI of 0.38
(0.22 to 0.52). The exercise-induced fall in ABPI
was lower in patients after GTN compared with
placebo (P = .0001). When the placebo maximum
ankle pressure was compared with the GTN maxi-
mum ankle pressure, there was no significant differ-
ence (P = .3), and when the brachial pressures were
compared, there was no significant drop in the pres-
sure after GTN compared with placebo (P = .157).
Only 1 patient had a headache, and because the
study design required placebo and GTN to be
administered in rapid succession, it was not possible
to determine whether this occurred with GTN or
placebo.
Study 2. To exclude possible temporal and car-
ryover effects, results were first analyzed according
to whether GTN or placebo was given first. These
results are summarized in Table III and indicate that
no such effects had occurred. For the entire group,
the median ABPI at rest was 0.57 (range, 0.46 to
0.64). The median CDS after placebo and GTN
spray were identical at 70 m (range, 50 to 80 m for
placebo and 50 to 85 m for GTN; P = .5). The
MWD after placebo was 105 m (80 to 172.5 m),
and the MWD after GTN was 125 m (90 to 202.5
m; Fig 4). There was a significant improvement
(19%) with GTN (P = .0084). Three patients in this
study had headache, all occurring after GTN.
DISCUSSION
Assessments of the long-term clinical effects of a
drug on claudication are notoriously difficult. One of
the main reasons for this is that many patients
improve spontaneously, usually within 12 months of
the onset of symptoms.8 The selection of patients
who would benefit from intervention is difficult, and
because drug therapy has in the past proved to be dis-
appointing, most patients are managed conservative-
ly. The aim of study 1 was to assess the objective
effect of GTN on the ABPI after exercise in patients
with intermittent claudication. The design of both
studies took into account the short half-life of the
GTN spray, which is 2.5 minutes (as provided by
Lipha Pharmaceuticals Limited). We have shown
how the ABPI after exercise decreases less with GTN
compared with placebo. The biggest contribution to
this is the brachial pressure. In all patients after exer-
cise, the brachial pressure increased; however, this
increase was less with GTN than with placebo (P =
.016). Thus, although the brachial pressure does not
rise as much with GTN, the index improves as the
ankle pressure remains much the same. Measurement
of the ABPI after exercise is a reliable noninvasive
method of quantifying exercise ischemia in patients
with intermittent claudication.6,7 The importance of
the ABPI is that because it is a ratio, it allows a com-
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Fig 3. The change in ABPI as shown in study 1. Vertical
lines represent interquartile range with median values.
Fig 4. The MWD and CD in meters as shown in study 2.
Vertical lines represent interquartile range with median
values.
parison of the degree of ischemia in patients with dif-
fering systemic arterial pressures. The implication of
this is that GTN produces an improvement in the
ABPI after exercise, but this may be due to its sys-
temic effect on arterial pressure rather than to local
actions on the arteries within the leg. 
For patients, the distance they can walk before
the onset of pain (CD) and distance they can walk
before the pain forces them to stop walking (MWD)
are the important determinants of the degree of dis-
ability caused by the arterial disease. It is unclear
why in study 2 GTN should improve the MWD but
not the CD. However, the MWD is the most impor-
tant to the patient, and this increased by 19% after a
single dose, which can be repeated as necessary. We
are currently investigating the effect of repeated
doses on the MWD, and this should provide data on
the true clinical benefit.
GTN is inexpensive and well tolerated and has
been proved to be simple to use. Further investigation
is required regarding the mechanism of action and
clinical effectiveness in the long term if GTN is to be
used in the treatment of intermittent claudication.
In conclusion, we have shown that a single dose
of GTN before exercise can improve the ABPI and
MWD. The mechanism for this and the clinical
application remain to be determined.
The GTN and placebo spray were kindly provided by
E. Merck Pharmaceuticals Ltd.
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